Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study

2014 ◽  
Vol 25 (4) ◽  
pp. 1369-1378 ◽  
Author(s):  
P. Hadji ◽  
A. Kauka ◽  
M. Ziller ◽  
K. Birkholz ◽  
M. Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

2013 ◽  
Author(s):  
Peyman Hadji ◽  
Anette Kauka ◽  
Thomas Bauer ◽  
Katrin Birkholz ◽  
Monika Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

2008 ◽  
Vol 9 (9) ◽  
pp. 840-849 ◽  
Author(s):  
Michael Gnant ◽  
Brigitte Mlineritsch ◽  
Gero Luschin-Ebengreuth ◽  
Franz Kainberger ◽  
Helmut Kässmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Endocrine Therapy ◽  
Bone Mineral ◽  
Early Stage ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Mineral Density

scholarly journals Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

2011 ◽  
Vol 47 (5) ◽  
pp. 683-689 ◽  
Author(s):  
C.L. Shapiro ◽  
S. Halabi ◽  
V. Hars ◽  
L. Archer ◽  
D. Weckstein ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Adjuvant Chemotherapy ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Ovarian Failure ◽  
Mineral Density

P16 Adjuvant Goserelin depot in premenopausal women with early breast cancer: Ovarian function, bone mineral density and survival. Preliminary data

1998 ◽  
Vol 34 ◽  
pp. S18
Author(s):  
A. De Matteis ◽  
G. D'Aiuto ◽  
G. Landi ◽  
F. Nuzzo ◽  
V. Labonia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Preliminary Data ◽  
Ovarian Function ◽  
Premenopausal Women ◽  
Mineral Density

scholarly journals Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer

2006 ◽  
Vol 91 (10) ◽  
pp. 3941-3946 ◽  
Author(s):  
J. Eng-Wong ◽  
J. C. Reynolds ◽  
D. Venzon ◽  
D. Liewehr ◽  
S. Gantz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Spine Density ◽  
Mineral Density ◽  
Percent Change ◽  
Increased Risk ◽  
The Mean

Abstract Context: Raloxifene is a promising breast cancer prevention agent in postmenopausal women at increased risk for breast cancer. The effects of raloxifene in premenopausal women are unknown. Objective: We evaluated the effect of raloxifene in premenopausal women at increased risk for breast cancer on bone mineral density (BMD). Design: This was a phase II clinical trial. Setting: This study was conducted at an academic medical center. Participants: Thirty-seven premenopausal women at increased risk for breast cancer enrolled in the trial. Thirty subjects began treatment and 27 were evaluable. Intervention: Raloxifene (60 mg daily) and elemental calcium (500 mg daily) were given for 2 yr. Subjects were followed up off medications for 1 yr. Main Outcome Measure: The primary end point was the intrasubject percent change in BMD at 1 yr measured by dual-energy x-ray absorptiometry. Results: The mean baseline lumbar spine density was 1.027 g/cm2. Lumbar spine density decreased 2.3% at 1 yr (P < 0.00001) and 3.5% at 2 yr (P < .00001). Percent change from yr 2 to 3 was +1.4%. The mean baseline total hip bone density was 0.905 g/cm2. Total hip density decreased 0.3% at 1 yr and 1.0% at 2 yr (P = 0.033). Percent change from yr 2 to 3 was +1.7%. Conclusions: Raloxifene use is associated with a decrease in BMD in premenopausal women at increased risk for breast cancer. The clinical significance of this decrease is unknown and is attenuated with stopping raloxifene.

Sign in / Sign up

Export Citation Format

Share Document